Trials / Completed
CompletedNCT06674070
SCN2A Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Population(Pakistan)
SCN2A, rs2304016 Polymorphisms Are Associated With Response to Valproic Acid in Paediatric Epilepsy Patients (Pakistan)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- Riphah International University · Academic / Other
- Sex
- All
- Age
- 1 Month – 12 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this Observational study was to identify the effect of SCN2A gene polymorphism in the Paediatric epileptic Pakistani population. The main question it aims to answer is: to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid Participants were prescribed Valproic acid after diagnosis of epilepsy.
Detailed description
This observational study aimed to identify the effect of SCN2A rs2304016 gene polymorphism in the Paediatric epileptic population. The main question it aims to answer is: • to evaluate the effect of this genetic polymorphism on the clinical efficacy of Valproic acid The participants' blood samples were taken and further genotyping was performed using conventional tetraARMS PCR. The results were visualized by gel electrophoresis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Valproic Acid | syrup/ tablet EPIVAL (250mg |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-07-31
- Completion
- 2024-08-31
- First posted
- 2024-11-05
- Last updated
- 2024-11-05
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT06674070. Inclusion in this directory is not an endorsement.